Literature DB >> 22405628

Evidence of an oncogenic gammaherpesvirus in domestic dogs.

Shih-Hung Huang1, Philip J Kozak, Jessica Kim, Georges Habineza-Ndikuyeze, Charles Meade, Anita Gaurnier-Hausser, Reema Patel, Erle Robertson, Nicola J Mason.   

Abstract

In humans, chronic infection with the gammaherpesvirus Epstein-Barr virus is usually asymptomatic; however some infected individuals develop hematological and epithelial malignancies. The exact role of EBV in lymphomagenesis is poorly understood partly because of the lack of clinically relevant animal models. Here we report the detection of serological responses against EBV capsid antigens in healthy dogs and dogs with spontaneous lymphoma and that dogs with the highest antibody titers have B cell lymphoma. Moreover, we demonstrate the presence of EBV-like viral DNA and RNA sequences and Latent Membrane Protein-1 in malignant lymph nodes of dogs with lymphoma. Finally, electron microscopy of canine malignant B cells revealed the presence of classic herpesvirus particles. These findings suggest that dogs can be naturally infected with an EBV-like gammaherpesvirus that may contribute to lymphomagenesis and that dogs might represent a spontaneous model to investigate environmental and genetic factors that influence gammaherpesvirus-associated lymphomagenesis in humans. Copyright Â
© 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22405628      PMCID: PMC4592777          DOI: 10.1016/j.virol.2012.02.013

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  67 in total

1.  Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.

Authors:  J Chodosh; Y j Gan; V P Holder; J W Sixbey
Journal:  Virology       Date:  2000-01-20       Impact factor: 3.616

2.  Is EBV persistence in vivo a model for B cell homeostasis?

Authors:  G Khan; E M Miyashita; B Yang; G J Babcock; D A Thorley-Lawson
Journal:  Immunity       Date:  1996-08       Impact factor: 31.745

3.  NEMO-binding domain peptide inhibits constitutive NF-κB activity and reduces tumor burden in a canine model of relapsed, refractory diffuse large B-cell lymphoma.

Authors:  Anita Gaurnier-Hausser; Reema Patel; Albert S Baldwin; Michael J May; Nicola J Mason
Journal:  Clin Cancer Res       Date:  2011-05-24       Impact factor: 12.531

4.  Discovery of Epstein-Barr virus (EBV)-encoded RNA signal and EBV nuclear antigen leader protein DNA sequence in pet dogs.

Authors:  Shiow-Her Chiou; Kuan-Chih Chow; Chih-Huan Yang; Shu-Fen Chiang; Chun-Hao Lin
Journal:  J Gen Virol       Date:  2005-04       Impact factor: 3.891

5.  CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells.

Authors:  L Yang; S Maruo; K Takada
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Immunohistochemical demonstration of different latent membrane protein-1 epitopes of Epstein-Barr virus in lymphoproliferative diseases.

Authors:  N M Jiwa; J J Oudejans; D F Dukers; W Vos; A Horstman; P van der Valk; J M Middledorp; J M Walboomers; C J Meijer
Journal:  J Clin Pathol       Date:  1995-05       Impact factor: 3.411

Review 7.  Translation of new cancer treatments from pet dogs to humans.

Authors:  Melissa Paoloni; Chand Khanna
Journal:  Nat Rev Cancer       Date:  2008-02       Impact factor: 60.716

8.  Analysis of Epstein-Barr viral genomes in lymphoid malignancy using Southern blotting, polymerase chain reaction and in situ hybridization.

Authors:  K Ohshima; M Kikuchi; F Eguchi; Y Masuda; Y Sumiyoshi; H Mohtai; M Takeshita; N Kimura
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1990

9.  Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

Authors:  R Taub; I Kirsch; C Morton; G Lenoir; D Swan; S Tronick; S Aaronson; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

10.  Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood.

Authors:  Uk Yeol Moon; Su Jin Park; Sang Taek Oh; Wan-Uk Kim; Sung-Hwan Park; Sang-Heon Lee; Chul-Soo Cho; Ho-Youn Kim; Won-Keun Lee; Suk Kyeong Lee
Journal:  Arthritis Res Ther       Date:  2004-05-07       Impact factor: 5.156

View more
  6 in total

Review 1.  Canine lymphoma as a comparative model for human non-Hodgkin lymphoma: recent progress and applications.

Authors:  Daisuke Ito; Aric M Frantz; Jaime F Modiano
Journal:  Vet Immunol Immunopathol       Date:  2014-02-24       Impact factor: 2.046

Review 2.  Man's best friend: what can pet dogs teach us about non-Hodgkin's lymphoma?

Authors:  Kristy L Richards; Steven E Suter
Journal:  Immunol Rev       Date:  2015-01       Impact factor: 12.988

3.  Gammaherpesviruses and canine lymphoma: no evidence for direct involvement in commonly occurring lymphomas.

Authors:  Elspeth M Waugh; Alice Gallagher; Karen A McAulay; Joaquim Henriques; Margarida Alves; Adam J Bell; Joanna S Morris; Ruth F Jarrett
Journal:  J Gen Virol       Date:  2015-02-26       Impact factor: 3.891

4.  Lack of Association Between Epstein-Barr Virus and Mammary Tumours in Dogs.

Authors:  Gustavo A Roa López; Jhon Jairo Suárez; Paola Barato; Noel Verján García
Journal:  J Vet Res       Date:  2018-12-10       Impact factor: 1.744

5.  Epidemiology and pathological progression of erythematous lip lesions in captive sun bears (Helarctos malayanus).

Authors:  Kirsty Officer; Mathieu Pruvot; Paul Horwood; Daniela Denk; Kris Warren; Vibol Hul; Nhim Thy; Nev Broadis; Philippe Dussart; Bethany Jackson
Journal:  PLoS One       Date:  2020-12-01       Impact factor: 3.240

6.  Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris.

Authors:  Marie Mooney; Jeffrey Bond; Noel Monks; Emily Eugster; David Cherba; Pamela Berlinski; Steve Kamerling; Keith Marotti; Heather Simpson; Tony Rusk; Waibhav Tembe; Christophe Legendre; Hollie Benson; Winnie Liang; Craig Paul Webb
Journal:  PLoS One       Date:  2013-04-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.